WHO ICTRP trial
A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus…
NL-OMON33926 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON33926 |
|---|---|
| Public title | A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer |
| Scientific title | A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer - Gemcitabine versus AG-013736 with pancreascancer |
| Primary sponsor | PRA International |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | Pancreatic cancer;10014713;Pancreatic cancer |
| Interventions | No additional invasive interventions are needed as archived tumor samples, taken in pre-study period, will be used. ;AG-013736;First-Line;Gemcitabine;Metastatic Pancreascancer |
| Registration date | Sep 15, 2009 |
| Target size | 12 |
| Secondary IDs | 2007-001568-66;NL19140.018.07 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: